The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination

The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination

Despite extensive preclinical evidence that peroxisome proliferator-activated receptor (PPAR)γ activation protects against tumourigenesis, results from a few clinical trials using PPARγ ligands as monotherapy show modest success. In spite of this, several groups reported exciting results with therap...

Full description

Saved in:

Bibliographic Details
Main Authors:	Graham Skelhorne-Gross, Christopher J. B. Nicol
Format:	Article
Language:	English
Published:	Wiley 2012-01-01
Series:	PPAR Research
Online Access:	http://dx.doi.org/10.1155/2012/946943
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases
by: Ajit A. Kulkarni, et al.
Published: (2012-01-01)

Homocysteine and Hypertension in Diabetes: Does PPARγ Have a Regulatory Role?
by: Utpal Sen, et al.
Published: (2010-01-01)

PPARγ Ligands Regulate Noncontractile and Contractile Functions of Airway Smooth Muscle: Implications for Asthma Therapy
by: Chantal Donovan, et al.
Published: (2012-01-01)

Underlying Anticancer Mechanisms and Synergistic Combinations of Phytochemicals with Cancer Chemotherapeutics: Potential Benefits and Risks
by: Muhammad Ayaz, et al.
Published: (2022-01-01)

Rosiglitazone, a Ligand to PPARγ, Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation
by: María Sánchez-Aguilar, et al.
Published: (2019-01-01)

PPARγ and PPARδ as Modulators of Neoplasia and Cell Fate
by: Robert I. Glazer, et al.
Published: (2008-01-01)

PPARγ in Inflammatory Bowel Disease
by: Vito Annese, et al.
Published: (2012-01-01)

15-Deoxy-∆-12,14-Prostaglandin J2 (15d-PGJ2), an Endogenous Ligand of PPAR-γ: Function and Mechanism
by: Jingjing Li, et al.
Published: (2019-01-01)

PPARγ and Its Role in Cardiovascular Diseases
by: Mini Chandra, et al.
Published: (2017-01-01)

Therapeutic Implications of PPARγ in Cardiovascular Diseases
by: Hiroshi Hasegawa, et al.
Published: (2010-01-01)

Thiazolidinediones on PPARγ: The Roles in Bone Remodeling
by: Wei Wei, et al.
Published: (2011-01-01)

Resolving the Two “Bony” Faces of PPAR-γ
by: Beata Lecka-Czernik, et al.
Published: (2006-01-01)

Therapeutic Implications of PPARγ in Human Osteosarcoma
by: Eric R. Wagner, et al.
Published: (2010-01-01)

The Model of PPARγ-Downregulated Signaling in Psoriasis
by: Vladimir Sobolev, et al.
Published: (2020-01-01)

Balancing CIK Cell Cancer Immunotherapy and PPAR Ligands: One Potential Therapeutic Application for CNS Malignancies
by: Kira Vordermark, et al.
Published: (2024-12-01)

Modes-of-Action Related to Repeated Dose Toxicity: Tissue-Specific Biological Roles of PPARγ Ligand-Dependent Dysregulation in Nonalcoholic Fatty Liver Disease
by: Merilin Al Sharif, et al.
Published: (2014-01-01)

PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors
by: Elisabetta Benedetti, et al.
Published: (2010-01-01)

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
by: Tamotsu Tsukahara
Published: (2012-01-01)

To Live or to Die: Prosurvival Activity of PPARγ in Cancers
by: Y. Lynn Wang, et al.
Published: (2008-01-01)

PPAR-γ Signaling Crosstalk in Mesenchymal Stem Cells
by: Ichiro Takada, et al.
Published: (2010-01-01)

Fine-Tuning Reception in the Bone: PPARγ and Company
by: Z. Elizabeth Floyd, et al.
Published: (2006-01-01)

PPARγ and Its Agonists in Chronic Kidney Disease
by: Yuhua Ma, et al.
Published: (2020-01-01)

PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
by: Sarawin Harnchoowong, et al.
Published: (2017-01-01)

Identification of Bexarotene as a PPARγ Antagonist with HDX
by: David P. Marciano, et al.
Published: (2015-01-01)

PPARγ in Bacterial Infections: A Friend or Foe?
by: Aravind T. Reddy, et al.
Published: (2016-01-01)

Protective Actions of PPAR-γ Activation in Renal Endothelium
by: Peter E. Westerweel, et al.
Published: (2008-01-01)

Combination PPARγ and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2
by: Joshua P. Klopper, et al.
Published: (2010-01-01)

Pharmacological and Toxicological Advances in PPAR-Related Medicines
by: Yuji Kamijo, et al.
Published: (2012-01-01)

Corrigendum to “PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors”
by: Elisabetta Benedetti, et al.
Published: (2019-01-01)

PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases
by: Yongchun Shen, et al.
Published: (2012-01-01)

Combined Effects of PPARγ Agonists and Epidermal Growth Factor Receptor Inhibitors in Human Proximal Tubule Cells
by: Katherine Pegg, et al.
Published: (2013-01-01)

PPARγ and the Innate Immune System Mediate the Resolution of Inflammation
by: Amanda Croasdell, et al.
Published: (2015-01-01)

Review of the Structural and Dynamic Mechanisms of PPARγ Partial Agonism
by: Alice J. Kroker, et al.
Published: (2015-01-01)

Solution Structures of PPARγ2/RXRα Complexes
by: Judit Osz, et al.
Published: (2012-01-01)

PPARγ as a Novel Therapeutic Target in Lung Cancer
by: Aravind T. Reddy, et al.
Published: (2016-01-01)

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
by: Zhanjun Jia, et al.
Published: (2014-01-01)

The Role of PPARγ in Helicobacter pylori Infection and Gastric Carcinogenesis
by: Jong-Min Lee, et al.
Published: (2012-01-01)

Mechanisms Mediating the Effects of γ-Tocotrienol When Used in Combination with PPARγ Agonists or Antagonists on MCF-7 and MDA-MB-231 Breast Cancer Cells
by: Abhita Malaviya, et al.
Published: (2013-01-01)

The Modulation of PPARγ1 and PPARγ2 mRNA Expression by Ciglitazone in CD3/CD28-Activated Naïve and Memory CD4+ T Cells
by: Mohd Nor Norazmi, et al.
Published: (2012-01-01)

The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria
by: Lena Serghides
Published: (2012-01-01)